Global In Silico Clinical Trial Market 2023-2029

In silico clinical trials refers to the development of patient-specific models to form virtual cohorts for testing the safety and efficacy of new drugs and of new medical devices. Moreover, it could be envisaged that a virtual set of patients could complement a clinical trial (reducing the number of enrolled patients and improving statistical significance), and advise clinical decisions. A chief advantage of in silico clinical trials is the substantial cost savings. The market for in silico clinical trial worldwide is expected to reach USD 4,536 million by 2029, recording a CAGR of 7.5% over the forecast period as per the latest report by Gen Consulting Company. The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global in silico clinical trial market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the therapeutic area, phase, industry, and region. The global market for in silico clinical trial can be segmented by therapeutic area: cardiology, diabetes, infectious diseases, neurology, oncology, others. The oncology segment is estimated to account for the largest share of the global in silico clinical trial market. In silico clinical trial market is further segmented by phase: phase I, phase II, phase III, phase IV. The phase II segment held the largest revenue share in 2022. Based on industry, the in silico clinical trial market is segmented into: medical devices, pharmaceuticals. Globally, the medical devices segment made up the largest share of the in silico clinical trial market. On the basis of region, the in silico clinical trial market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global in silico clinical trial market in 2022. Market Segmentation By therapeutic area: cardiology, diabetes, infectious diseases, neurology, oncology, others By phase: phase I, phase II, phase III, phase IV By industry: medical devices, pharmaceuticals By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America The report has also analysed the competitive landscape of the global in silico clinical trial market with some of the key players being Abzena Limited, Aganitha AI Inc., Certara, Inc., Codexis Inc., Creative Biolabs, Inc., Dassault Systemes SE, Evotec SE, GNS Healthcare Inc ., Immunetrics Inc., Insilico Biotechnology AG (Yokogawa Electric Corporation), Insilico Medicine Inc., InSilicoTrials Technologies SpA, Instem plc (LeadScope, Inc.), Novadiscovery SAS, Siemens AG, ZMT Zurich MedTech AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market. *REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES Scope of the Report • To analyze and forecast the market size of the global in silico clinical trial market. • To classify and forecast the global in silico clinical trial market based on therapeutic area, phase, industry, region. • To identify drivers and challenges for the global in silico clinical trial market. • To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global in silico clinical trial market. • To identify and analyze the profile of leading players operating in the global in silico clinical trial market. Why Choose This Report • Gain a reliable outlook of the global in silico clinical trial market forecasts from 2023 to 2029 across scenarios. • Identify growth segments for investment. • Stay ahead of competitors through company profiles and market data. • The market estimate for ease of analysis across scenarios in Excel format. • Strategy consulting and research support for three months. • Print authentication provided for the single-user license.